Update on the treatment of neuroendocrine tumors

Expert Review of Anticancer Therapy

Volumn 3, Issue 5, 2003, Pages 631-642

  Bajetta, Emilio ^a   Procopio, Giuseppe ^a   Ferrari, Leonardo ^a   Catena, Laura ^a   Del Vecchio, Michele ^a   Bombardieri, Emilio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Anthracyclines; Dacarbazine; Etoposide; Fluoropyrimidines; Interferon ; Lanreotide; Neuroendocrine tumors; Octreotide; Platinum analogs; Somatostatin analogs

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANGIOPEPTIN; ANTINEOPLASTIC AGENT; CAPECITABINE; CHLOROZOTOCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; INTERLEUKIN 12; IRINOTECAN; MITOMYCIN C; MITOXANTRONE; OCTREOTIDE; OXALIPLATIN; PACLITAXEL; PENTETREOTIDE; RECOMBINANT ALPHA INTERFERON; SOMATOSTATIN DERIVATIVE; SOMATULINE AUTOGEL; STREPTOZOCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; YTTRIUM 90;

ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTHRALGIA; ARTIFICIAL EMBOLISM; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CRYOTHERAPY; DIARRHEA; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG STRUCTURE; FEBRILE NEUTROPENIA; FEVER; FLU LIKE SYNDROME; GALLBLADDER DISEASE; GALLSTONE; GENETIC HETEROGENEITY; HEPATIC ARTERY LIGATION; HISTOPATHOLOGY; HUMAN; LIVER DYSFUNCTION; MALAISE; MYALGIA; NEUROENDOCRINE TUMOR; PARAGANGLIOMA; PHEOCHROMOCYTOMA; REVIEW; STEADY STATE; SURVIVAL RATE; THROMBOCYTOPENIA; VIRAL GENE DELIVERY SYSTEM;

EID: 0242319611     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.3.5.631     Document Type: Review

References (105)

1. Rindi G, Azzoni C, LaRosa S et al. ECL tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. Gastroenterology 116, 532-542 (1999).
2. Wick MR, Ritter JH. Neuroendocrine neoplasia of the lung: key references. Ann. Thorac. Surg. 69, 307-308 (2000).
3. Solcia E, Klöppel G, Sobin LH et al. Histological typing of neuroendocrine tumors, 2nd edition. Springer, New York, USA (2000).
4. Öberg K. Carcinoid tumors: molecular genetics, tumor biology and update of diagnosis and treatment. Curr. Opin. Oncol. 14, 38-45 (2002).
5. Janson ET, Öberg K. Malignant neuroendocrine tumors. Cancer Chemother. Biol. Response Modif. 20, 463-470 (2002).
6. Ahlman H, Nilsson O. The gut as the largest endocrine organ in the body. Ann. Oncol. 12(Suppl. 2), S63-S68 (2001).
7. Wulbrand U, Wied M, Zöfel P, Göke B, Arnold R, Fehman H-C. Growth factor receptor expression in human gastroenteropancreatic neuroendocrine tumours. Eur. J. Clin. Invest. 28, 1038-1049 (1998).
8. Shimizu T, Tanaka S, Haruma K et al. Growth characteristics of rectal carcinoid tumors. Oncology 59, 229-237 (2000).
9. Calender A. Molecular genetics of neuroendocrine tumors. Digestion 62, 3-18 (2000).
10. Cardillo MR, Filipo R, Monini S, Aliotta N, Barbara M. Transforming growth factor-β1 expression in human acoustic neuroma. Am. J. Otol. 20, 65-68 (1999).
11. Barbareschi M, Girlando S, Mauri FA et al. Tumor suppressor gene products, proliferation and differentiation markers in lung neuroendocrine neoplasms. J. Pathol. 166, 343-350 (1992).
12. Chaudhry A, Öberg K, Wilander E. A study of biological behavior based on the expression of a proliferating antigen in neuroendocrine tumors of the digestive system. Tumor Biol. 13, 27-35 (1992).
13. Costes V, Marty-Aué C, Piccot MC et al. Typical and atypical bronchopulmonary carcinoid tumors: a clinico-pathologic and Ki-67 labeling study. Hum. Pathol. 26, 740-745 (1995).
14. Granberg D, Wilander E, Öberg K, Skogseid B. Prognostic markers in patients with typical bronchial carcinoid tumors. J. Clin. Endocrinol. Metab. 85, 3425-3430 (2000).
15. Gentil Perret A, Mosnier JF, Buono JP et al. The relationship between MIB-1 proliferation index and outcome in pancreatic neuroendocrine tumors. Am. J. Clin. Pathol. 109, 286-293 (1998).
16. La Rosa S, Sessa F, Capella C et al. Prognostic criteria in nonfunctioning pancreatic endocrine tumours. Virchows Arch. 429, 323-333 (1996).
17. Makridis C, Öberg K, Lublin C et al. Surgical treatment of midgut carcinoid tumors. World J. Surg. 14, 377 (1990).
18. Sarmiento JM, Que FG. Hepatic surgery for metastases from neuroendocrine tumors. Surg. Oncol. Clin. N. Am. 12, 231-242 (2003).
19. Routley D, Ramage JK, McPeake J et al. Orthotopic liver transplantation in the treatment of metastatic neuroendocrine tumors of the liver. Liver Transpl. Surg. 1, 118-121 (1995).
20. Yao KA, Talamonti MS, Nemcek A et al. Indication and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery 130, 677-682 (2001).
21. Balestrero LM, Beaver CR, Rigas JR. Hypertensive crisis following meperidine administration and chemoembolization of a carcinoid tumor. Arch. Intern. Med. 160, 2394-2395 (2000).
22. Dominguez S, Denys A, Madeira I et al. Hepatic arterial chemoembolization with streptozotocin in patients with metastatic digestive endocrine tumors. Eur. J. Gastroenterol. Hepatol. 12, 151-157 (2000).
23. Zimmer C, Kienbaum P, Wiesemes R et al. Somatostatin does not prevent serotonin release and flushing during chemoembolization of carcinoid liver metastases. Anesthesiology 98, 1007-1011 (2003).
24. Roche A, Girish BV, De Baere T et al. Trans-catheter arterial chemoembolization as first line treatment for hepatic metastases from endocrine tumors. Eur. Radiol. 13, 136-140 (2003).
25. Schell SR, Camp ER, Caridi JG et al. Hepatic artery embolization for control of symptoms, octreotide requirements and tumor progression in metastatic carcinoid tumors. J. Gastrointest. Surg. 6, 664-670 (2002).
26. Siperstein AE, Berber E. Cryoablation, percutaneous alcohol injection and radiofrequency ablation for treatment of neuroendocrine tumor liver metastases. World J. Surg. 25, 693-696 (2001).
27. Berber E, Flesher N, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine tumor liver metastases. World J. Surg. 26, 985-990 (2002).
28. Hellman P, Ladjevardi S, Skogseid B et al. Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors. World J. Surg. 26, 1052-1056 (2002).
29. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 47, 207-214 (1981).
30. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate response to treatment in solid tumors. J. Natl Cancer Inst. 92, 205-216 (2000).
31. 2a. Cancer 72, 3099-3100 (1993).
32. Moertel CG, Kvols LK, O'Connel MJ. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variance of these neoplasms. Cancer 68, 227-232 (1991).
33. Mitry E, Baudin E, Ducreaux M et al. Treatment of poorly differentiated neuroendocrine tumors with etoposide and cisplatin. Br. J. Cancer 81, 1351 (2000).
34. Moertel CG, Lefkopoulo M, Lipsitz M, Hahn RG, Klaassen D. Streptozotocin-doxorubicin, streptozotocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N. Engl. J. Med. 326, 519-523 (1992).
35. Cheng PNM, Saltz LB. Failure to confirm major objective antitumor activity for streptozotocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 86, 944-948 (1999).
36. Bajetta E, Ferrari L, Procopio G et al. Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. Ann. Oncol. 13, 614-621 (2002).
37. Tai PT, Yu E, Winquist E et al. Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 cases. J. Clin. Oncol. 18, 2493-2499 (2000).
38. Averbuch SD, Steakley CS, Young RC et al. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine and dacarbazine. Ann. Int. Med. 109, 267-273 (1988).
39. Pederzoli P, Falconi M, Bonora A et al. Cytoreductive surgery in advanced endocrine tumours of the pancreas. Ital. J. Gastroenterol. Hepatol. 31(Suppl. 2), S207-S212 (1999).
40. Hou Z, Elasmar SA, Lozano R et al. A pilot study of irinotecan plus cisplatin in patients with metastatic high-grade neuroendocrine carcinoma. Proc. Am. Soc. Clin. Oncol. 22, 375 (2003).
41. Öberg K. Carcinoid tumors: current concepts in diagnosis and treatment. Oncologist 3, 339-345 (1998).
42. Di Bartolomeo M, Bajetta E, Buzzoni R et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology (ITMO) Group. Cancer 77, 402-408 (1996).
43. Patel YC, Greenwood MT, Panetta R et al. Mini review: the somatostatin receptor family. Life Sci. 57, 1249-1265 (1995).
44. Lamberts SWJ, Van der Lely AJ, de Herden WW et al. Octreotide. N. Engl. J. Med. 334, 246-254 (1996).
45. Imam H, Eriksson B, Lukinius A et al. Induction of apoptosis in neuroendocrine tumours of the digestive system during treatment with somatostatin analogues. Acta Oncol. 36, 607-614 (1997).
46. Rubin J, Ajani J, Schrimer W et al. Octreotide acetate long-acting formulation versus open-label sc. octreotide acetate in malignant carcinoid syndrome. J. Clin. Oncol. 17(2), 600-606 (1999).
47. O'Toole D, Ducreux M, Bommelaer G et al. Treatment of carcinoid syndrome. Cancer 88, 770-776 (2000).
48. Ricci S, Antonuzzo A, Galli L et al. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide. Ann. Oncol. 11, 1127-1130 (2000).
49. Raderer M, Kurtaran A, Scheithauer W, Fiebiger W, Weinlaender G, Oberhuber G. Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid. Oncology 60, 141-145 (2001).
50. Lightman S. Somatuline Autogel: an extended release lanreotide formulation. Hosp. Med. 63, 162-165 (2002).
51. Hejna M, Schmidinger M, Raderer M. The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing? Ann. Oncol. 13, 653-668 (2002).
52. Aparicio T, Ducreux M, Baudin E et al. Antitumor activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur. J. Cancer 37, 1014-1019 (2001).
53. Bruns C, Lewis I, Briner U, Memo-Tetang G, Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur. J. Endocrinol. 146, 707-716 (2002).
54. Detjen KM, Kehrberger JP, Drost A et al. Interferon-γ inhibits growth of human neuroendocrine carcinoma cells via induction of apoptosis. Int. J. Oncol. 21, 1133-1140 (2002).
55. Zhou Y, Wang S, Yue BG, Gobl A, Öberg K. Effects of interferon-α on the expression of p21 cip1/waf1 and cell cycle distribution in carcinoid, tumors. Cancer Invest. 20, 348-356 (2002).
56. Detjen KM, Welzel M, Farwig K et al. Molecular mechanism of interferon-α-mediated growth inhibition in human neuroendocrine tumor cells. Gastroenterology 118, 735-748 (2000).
57. 2a. Acta Oncol. 32, 235-238 (1993).
58. Öberg K. Interferon in the management of neuroendocrine GEP tumours. Digestion 62(Suppl. 1), 92-97 (2000).
59. Bajetta E, Procopio G, Buzzoni R, Catena L, Ferrari L, Del Vecchio M. Advances in diagnosis and therapy of neuroendocrine tumors. Expert Rev. Anticancer Ther. 1, 89-99 (2001).
60. Öberg K. Neuroendocrine gastrointestinal tumors - a condensed overview of diagnosis and treatment. Ann. Oncol. 10(Suppl. 2), S3-S8 (1999).
61. Moertel CG, Rubin J, Kvols LK. Therapy of metastatic carcinoid tumour and the management of carcinoid with recombinant leukocyte interferon-α. J. Clin. Oncol. 7, 865-868 (1989).
62. Kirkwood JM, Ernstoff MS. Interferons in the treatment of human cancer. J. Clin. Oncol. 2, 336-352 (1984).
63. Levens WJ, Fischer N, Ingehag W, Rubben H. Adverse reactions in long-term interferon treatment. Semin. Surg. Oncol. 4, 204-206 (1988).
64. Frank M, Klose KJ, Wied M, Ishaque N, Schade-Brittinger C, Arnold R. Combination therapy with octreotide and α-interferon: effect on tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gastroenterology 94, 155-159 (1999).
65. Fjällskog ML, Sundin A, Westlin JE, Öberg K, Janson ET, Eriksson B. Treatment of malignant endocrine pancreatic tumours with combination of α-interferon and somatostatin analogues. Med. Oncol. 19, 35-42 (2002).
66. 2b in the palliation of malignant neuroendocrine tumors. J. Clin. Oncol. 13, 1486-1492 (1995).
67. Ahlgren JD, Lenning PD, Gulli JJ, Heim WJ, Lokich JJ, Fryer D. Protracted infusional 5-FU (PIF) + α2b-interferon (α-IFN) in metastatic carcinoid: updated experience with Mid-Atlantic Oncology Program (MAOP) study 5190. Proc. Am. Soc. Clin. Oncol. 14, 219 (1995).
68. Janson ET, Rönnblom L, Ahlström H et al. Treatment of α-interferon in combination with streptozotocin and doxorubicin in patients with malignant carcinoid tumors: a randomized trial. Ann. Oncol. 3, 635-638 (1992).
69. Zhou Y, Gobl A, Wang S et al. Expression of p68 protein kinase and its prognostic significance during IFN-α therapy in patients with carcinoid tumours. Eur. J. Cancer 34, 2046-2052 (1998).
70. 131I-metaiodobenzylguanidine (mIBG) in treatment of neuroendocrine tumours (Experience of National Cancer Institute of Milan . Quart. J. Nucl. Med. 44, 77-87 (2000).
71. Kaltsas GA, Mukherjee JJ, Grossman AB. The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours. Ann. Oncol. 12(Suppl. 2), S47-S50 (2001).
72. Virgolini I, Patri P, Novotny C et al. Comparative somatostatin receptor scintigraphy using In-111-DOTA-lanreotide and In-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy. Ann. Oncol. 12(Suppl. 2), S41-S45 (2001).
73. de Herder WW, Lamberts WJ. Somatostatin and somatostatin analogues: diagnostic and therapeutic uses. Curr. Opin. Oncol. 14, 53-57 (2002).
74. Olle A, Mueller-Braud J, Della S et al. Yttrium-90 labelled somatostatin analogue for cancer treatment. Lancet 351, 417-418 (1998).
75. Virgolini I, Britton K, Buscombe J et al. In- and Y-DOTA-lanreotide: results and implication of the MAURITIUS trial. Semin. Nucl. Med. 32, 148-155 (2002).
76. Kwekkeboom DJ, Bakker WH, Kam BL et al. Treatment of patients with gastroenteropancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA-Tyr3]octreotate. Eur. J. Nucl. Med. Mol. Imaging 30, 417-422 (2003).
77. Zhang R, DeGroote LJ. Genetic immunotherapy of established tumours with adenoviral vectors transducing murine interleukin-12 (mIL12) subunits in a rat medullary thyroid carcinoma model. Clin. Endocrinol. 52, 687-694 (2001).
78. Larsson G, Sjödén PO, Öberg K, von Essen L. Importance-satisfaction discrepancies are associated with health-related quality of life in five-year survivors of endocrine gastrointestinal tumours. Ann. Oncol. 10, 1321-1327 (1999).
79. Larsson G, von Essen L, Sjödén PO. Health-related quality of life in patients with endocrine tumours of the gastrointestinal tract. Acta Oncol. 38, 481-490 (1999).
80. Fjällskog ML, Lejonklou MH, Öberg KE, Eriksson BK, Janson ET. Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin. Cancer Res. 9, 1469-1473 (2003).
81. Hobday J, Rubin R, Goldberg C, Erlichman R, Lloyd R. Molecular markers in metastatic gastrointestinal neuroendocrine tumors. Proc. Am. Soc. Clin. Oncol. 22, 269 (2003).
82. Moertel CG. An odyssey in the land of small tumors. J. Clin. Oncol. 5, 1503-1522 (1987).
83. Öberg K, Norheim I, Lundqvist G et al. Cytotoxic treatment in patients with malignant carcinoid tumors. Response to streptozotocin alone or in combination with 5-FU. Acta Oncol. 26, 429-432 (1987).
84. Silver BA, Barlock AL, Lippman ME, Anderson T, Fisher RI. Phase II trial of chlorozotocin in malignant melanoma, breast cancer and other solid tumors. Cancer Treat. Rep. 66, 1229-1230 (1982).
85. Engström PF, Lavin PT, Folsch E et al. Streptozotocin (STZ) + fluorouracil (FU) versus adriamycin (AD) for metastatic carcinoid tumors. Proc. Am. Assoc. Cancer Res. 24, 551 (1983).
86. von Hazel GA, Rubin J, Moertel CG. Treatment of metastatic carcinoid tumor with D-actinomycin or dacarbazine. Cancer Treat. Rep. 67, 583-585 (1983).
87. Ritzel U, Leonhardt U, Stöckman F, Ramadori G. Treatment of metastasized midgut carcinoids with dacarbazine. Am. J. Gastroenterol. 90, 627-631 (1995).
88. Bukowski RM, Tangen CM, Peterson RF et al. Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. Cancer 73, 1505-1508 (1994).
89. Kulke M, Fuchs C, Stuart K et al. Phase II study of docetaxel in patients with metastatic carcinoid tumors. Proc. Am. Soc. Clin. Oncol. 19, 1233 (2000).
90. Porter AT, Ostrowski MJ. Medullary carcinoma of the thyroid treated by low-dose adriamycin. Br. J. Clin. Pract. 44, 517-518 (1990).
91. Moertel CG, Rubin J, O'Connel MJ. Phase II study of cisplatin therapy in patients with metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Treat. Rep. 70, 1459-1460 (1986).
92. Neijt JP, Lacave AJ, Splinter TAW et al. Mitoxantrone in metastatic apudomas: a Phase II study of the EORTC Gastrointestinal Cancer Co-operative Group. Br. J. Cancer 71, 106-108 (1995).
93. Ansell SM, Pitot HC, Burch PA, Kvols LY, Mattoney MR, Rubin J. A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumours. Cancer 91, 1543-1548 (2001).
94. Moertel CG, Hanley JA, Johnsson LA. Streptozotocin alone compared with streptozotocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N. Engl. J. Med. 303, 1189-1194 (1980).
95. Bukowski RM, Tangen C, Lee R et al. Phase II trial of chlorozotocin and fluorouracil in islet cell carcinoma: a South West Oncology Group Study. J. Clin. Oncol. 10, 1914-1918 (1992).
96. Rivera E, Ajani JA. Doxorubicin, streptozotocin and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma. Am. J. Clin. Oncol. 21, 36-38 (1998).
97. Bajetta E, Rimassa L, Carnaghi C et al. 5-fluorouracil, dacarbazine and epirubicin in the treatment of patients with neuroendocrine tumors. Cancer 83, 372-378 (1998).
98. Filosso PL, Ruffini E, Oliaro A, Papalia E, Donati G, Rena O. Long-term survival of atypical bronchial carcinoids with liver metastases treated with octreotide. Eur. J. Cardiothorac. Surg. 21, 913-917 (2002).
99. Saltz L, Trochanowski B, Buckley M et al. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumours. Cancer 72, 244-248 (1993).
100. Arnold R, Trautmann ME, Creutzfeldt W et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 38, 430-438 (1996).
101. Eriksson B, Renstrup J, Imam H, Öberg K. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumours: clinical and biological effect. Ann. Oncol. 8, 1041-1044 (1997).
102. Ruszniewski P, Ducreux M, Chayvialle JA et al. Treatment of the carcinoid syndrome with the long-acting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut 39, 279-283 (1996).
103. Wymenga AN, Eriksson B, Salmela PI et al. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumours and hormone-release symptoms. J. Clin. Oncol. 17, 1111-1117 (1999).
104. Faiss S, Rath U, Mansmann U et al. Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors. Digestion 60, 469-476 (1999).
105. Funa K, Alm GV, Rönnblom L, Öberg K. Evaluation of the natural killer cell-interferon system in patients with midgut carcinoid tumours treated with leukocyte interferon. Clin. Exp. Immunol. 53, 716-724 (1983).